QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.081711v1 313/2/831    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chaki, S. Articles by Thomsen, W. Search for Related Content PubMed PubMed Citation Articles by Chaki, S. Articles by Thomsen, W.

NEUROPHARMACOLOGY

Anxiolytic- and Antidepressant-Like Profile of ATC0065 and ATC0175: Nonpeptidic and Orally Active Melanin-Concentrating Hormone Receptor 1 Antagonists

Taisho Pharmaceutical Co., Ltd., Saitama, Japan (S.C., T.F., S.H.-O., M.N., T.S., M.I., K.K., K.O., Y.S., S.O.); and Arena Pharmaceuticals Inc., San Diego, California (A.J.G., T.-A.T., G.S., W.T.)

Melanin-concentrating hormone (MCH) is a cyclic peptide produced in the lateral hypothalamus. It has been implicated in a number of physiological processes including feeding behavior, energy balance, and the regulation of emotional states. Here, we report in vitro and in vivo profiles of ATC0065 [N²-[cis-4-({2-[4-bromo-2-(trifluoromethoxy)phenyl]ethyl}amino)cyclohexyl]-N⁴, N⁴-dimethylquinazoline-2,4-diamine dihydrochloride] and ATC0175 [N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide hydrochloride], newly synthesized MCH receptor 1 (MCHR1) antagonists. Both ATC0065 and ATC0175 had high affinities for human MCHR1 with IC₅₀ values of 15.7 ± 1.95 and 7.23 ± 0.59 nM, respectively. Both ATC0065 (IC₅₀ = 21.4 ± 1.57 nM) and ATC0175 (IC₅₀ = 13.5 ± 0.78 nM) showed potent antagonist activities at MCHR1, as assessed by MCH-increased guanosine 5'-O-(3-[³⁵S]thio)phosphate ([³⁵S]GTPS) binding to human MCHR1. Oral administration of ATC0065 (3–30 mg/kg) or ATC0175 (1–10 mg/kg) significantly reduced immobility time in the forced swimming test in rats, indicating antidepressant-like effects. Both ATC0065 and ATC0175 significantly reversed swim stress-induced anxiety in the elevated plus-maze test in rats and stress-induced hyperthermia in mice. ATC0175 significantly increased social interaction between unfamiliar rats and reduced separation-induced vocalizations in guinea pig pups, indicating anxiolytic potential. In contrast, ATC0065 and ATC0175 did not affect spontaneous locomotor activity or rotarod performance in rats. These findings indicate that ATC0065 and ATC0175 are potent and orally active MCHR1 antagonists with anxiolytic and antidepressant activity in rodents.

Address correspondence to: Dr. Shigeyuki Chaki, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku Saitama, Saitama 331-9530, Japan. E-mail: s.chaki{at}po.rd.taisho.co.jp

This article has been cited by other articles:

				D. R. Gehlert, K. Rasmussen, J. Shaw, X. Li, P. Ardayfio, L. Craft, T. Coskun, H. Y. Zhang, Y. Chen, and J. M. Witkin Preclinical Evaluation of Melanin-Concentrating Hormone Receptor 1 Antagonism for the Treatment of Obesity and Depression J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 429 - 438. [Abstract] [Full Text] [PDF]

				D. J. David, K. C. Klemenhagen, K. A. Holick, M. D. Saxe, I. Mendez, L. Santarelli, D. A. Craig, H. Zhong, C. J. Swanson, L. G. Hegde, et al. Efficacy of the MCHR1 Antagonist N-[3-(1-{[4-(3,4-Difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in Mouse Models of Anxiety and Depression following Acute and Chronic Administration Is Independent of Hippocampal Neurogenesis J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 237 - 248. [Abstract] [Full Text] [PDF]

				P. Pissios, R. L. Bradley, and E. Maratos-Flier Expanding the Scales: The Multiple Roles of MCH in Regulating Energy Balance and Other Biological Functions Endocr. Rev., October 1, 2006; 27(6): 606 - 620. [Abstract] [Full Text] [PDF]